Metabonomic evaluation of metabolic dysregulation in rats induced by PF 376304, a novel inhibitor of phosphoinositide 3-kinase

Chemical Research in Toxicology

Volumn 20, Issue 12, 2007, Pages 1871-1877

  Robertson, Donald G ^a,b   Datta, Kaushik ^a   Wells, Dale ^a   Egnash, Laura ^a   Robosky, Lora ^a   Manning, Matt ^a   Rohde, Cynthia ^a   Reily, Michael D ^a  

^a PFIZER INC   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; CITRIC ACID; CORTICOSTERONE; CREATINE; GLUCOSE; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; EVALUATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; INSULIN BLOOD LEVEL; MALE; METABOLIC DISORDER; MORTALITY; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; ENZYME INHIBITORS; FEMALE; GLUCOSE; GLYCOSURIA; HYPERGLYCEMIA; INSULIN; MALE; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES; TRIGLYCERIDES;

ANIMALIA; RATTUS;

EID: 38149081481     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx7002036     Document Type: Article

References (36)

1. Gibney, M. J., Walsh, M., Brennan, L., Roche, H. M., German, B., and van Ommen, B. (2005) Metabolomics in human nutrition: opportunities and challenges. Am. J. Clin. Nutr. 82, 497-503.
2. Griffin, J. L., and Nicholls, A. W. (2006) Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics 7, 1095-1107.
3. Schauer, N., and Fernie, A. R. (2006) Plant metabolomics: towards biological function and mechanism. Trends Plant Sci. 11, 508-516.
4. Robertson, D. G., Reily, M. D., and Baker, J. D. (2005) Metabonomics in preclinical drug development. Expert Opin. Drug Metab. Toxicol. 1, 363-376.
5. Robertson, D. G. (2005) Metabonomics in toxicology: a review. Toxicol. Sci. 85, 809-822.
6. Lindon, J. C., Holmes, E., and Nicholson, J. K. (2006) Metabonomics techniques and applications to pharmaceutical research & development. Pharm. Res. 23, 1075-1088.
7. Cantley, L. C. (2002) The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
8. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M. D. (2001) Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis and cancer. Annu. Rev. Cell Dev. Biol. 17, 615-675.
9. Cohen, P. (2006) The twentieth century struggle to decipher insulin signalling. Nat. Rev. Mol. Cell Biol. 7, 867-873.
10. Taniguchi, C. M., Emanuelli, B., and Kahn, C. R. (2006) Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85-96.
11. Vanhaesebroeck, B., Leevers, S. J., Panayotou, G., and Waterfield, M. D. (1997) Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem. Sci. 22, 267-272.
12. Chantry, D., Vojtek, A., Kashishian, A., Holtzman, D. A., Wood, C., Gray, P. W., Cooper, J. A., and Hoekstra, M. F. (1997) p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J. Biol. Chem. 272, 19236-19241.
13. Vanhaesebroeck, B., Welham, M. J., Kotani, K., Stein, R., Warne, P. H., Zvelebil, M. J., Higashi, K., Volinia, S., Downward, J., and Waterfield, M. D. (1997) P110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl. Acad. Sci. U.S.A. 94, 4330-4335.
14. Zhao, J. J., Cheng, H., Jia, S., Wang, L., Gjoerup, O. V., Mikami, A., and Roberts, T. M. (2006) The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 103, 16296-16300.
15. Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J., Withers, D. J., and Vanhaesebroeck, B. (2006) Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370.
16. Knight, Z. A., Gonzalez, B., Feldman, M. E., Zunder, E. R., Goldenberg, D. D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., Balla, T., Weiss, W. A., Williams, R. L., and Shokat, K. M. (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125, 733-747.
17. Brachmann, S. M., Ueki, K., Engelman, J. A., Kahn, R. C., and Cantley, L. C. (2005) Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell. Biol. 25, 1596-1607.
18. Yip, S. C., El-Sibai, M., Hill, K. M., Wu, H., Fu, Z., Condeelis, J. S., and Backer, J. M. (2004) Over-expression of the p110β but not p110α isoform of PI 3-kinase inhibits motility in breast cancer cells. Cell Motil. Cytoskeleton 59, 180-188.
19. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., Smith, A. J., and Vanhaesebroeck, B. (2002) Impaired B and T cell antigen receptor signaling in p110δ PI 3-kinase mutant mice. Science 297, 1031-1034.
20. Okkenhaug, K., Bilancio, A., Emery, J. L., and Vanhaesebroeck, B. (2004) Phosphoinositide 3-kinase in T cell activation and survival. Biochem. Soc. Trans. 32, 332-335.
21. Ward, S., Sotsios, Y., Dowden, J., Bruce, I., and Finan, P. (2003) Therapeutic potential of phosphoinositide 3-kinase inhibitors. Chem. Biol. 10, 207-213.
22. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., and Mills, G. B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discovery 4, 988-1004.
23. Ward, S. G., and Finan, P. (2003) Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3, 426-434.
24. Ruckle, T., Schwarz, M. K., and Rommel, C. (2006) PI3Kγ inhibition: towards an 'aspirin of the 21st century'? Nat. Rev. Drug Discovery 5, 903-918.
25. Seol, J. W., Lee, Y. J., Kang, H. S., Kim, I. S., Kim, N. S., Kwak, Y. G., Kim, T. H., Seol, D. W., and Park, S. Y. (2005) Wortmannin elevates tumor necrosis factor-related apoptosis-inducing ligand sensitivity in LNCaP cells through down-regulation of IAP-2 protein. Exp. Oncol. 27, 120-124.
26. Shimaya, A., Kovacina, K. S., and Roth, R. A. (2004) On the mechanism for neomycin reversal of wortmannin inhibition of insulin stimulation of glucose uptake. J. Biol. Chem. 279, 55277-55282.
27. Bradley, E. A., Clark, M. G., and Rattigan, S. (2007) Acute effects of wortmannin on insulin's hemodynamic and metabolic actions in vivo. Am. J. Physiol. 292, E779-E787.
28. Chirieac, D. V., Davidson, N. O., Sparks, C. E., and Sparks, J. D. (2006) PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice. Am. J. Physiol. 291, G382-G388.
29. Clayton, T. A., Lindon, J. C., Everett, J. R., Charuel, C., Hanton, G., Le Net, J. L., Provost, J. P., and Nicholson, J. K. (2003) An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria. Arch. Toxicol. 77, 208-217.
30. Clayton, T. A., Lindon, J. C., Everett, J. R., Charuel, C., Hanton, G., Le Net, J. L., Provost, J. P., and Nicholson, J. K. (2004) Hepatotoxin-induced hypercreatinaemia and hypercreatinuria: their relationship to one another, to liver damage and to weakened nutritional status. Arch. Toxicol. 78, 86-96.
31. Gartland, K. P., Bonner, F. W., Timbrell, J. A., and Nicholson, J. K. (1989) Biochemical characterization of p-aminophenol-induced nephrotoxic lesions in the F344 rat. Arch. Toxicol. 63, 97-106.
32. Anthony, M. L., Sweatman, B. C., Beddell, C. R., Lindon, J. C., and Nicholson, J. K. (1994) Pattern recognition classification of the site of nephrotoxicity based on metabolite data derived from proton nuclear magnetic resonance spectra of urine. Mol. Pharmacol. 46, 199-211.
33. Robertson, D. G., Reily, M. D., Sigler, R. E., Wells, D. F., Paterson, D. A., and Braden, T. K. (2000) Metabonomics: Evaluation of nuclear magnetic resonance (NMR) and pattern recognition technology for rapid in vivo screening of liver and kidney toxicants. Toxicol. Sci. 87, 326-337.
34. 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 10, 173-187.
35. Balcombe, J. P., Barnard, N. D., and Sandusky, C. (2004) Laboratory routines cause animal stress. Contemp. Top. Lab. Anim. Sci. 43, 42-51.
36. Vachon, P., and Moreau, J. P. (2001) Serum corticosterone and blood glucose in rats after two jugular vein blood sampling methods: comparison of the stress response. Contemp. Top. Lab. Anim. Sci. 40, 22-24.